Suzhou Yu's Pharmaceutical

Suzhou Yu's Pharmaceutical is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of innovative metabolic and endocrine therapies. The company focuses on multi-agonist small molecule drugs targeting the GLP-1, GCG, and GIP receptors for the treatment of type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Their lead candidate, YS-001, is an orally available small molecule GLP-1 receptor agonist designed to provide a more convenient alternative to injectable therapies. By leveraging expertise in medicinal chemistry and metabolic pathways, Suzhou Yu's Pharmaceutical aims to address significant unmet needs in the global metabolic disease market.